When was Eikon founded?

Eikon was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Eikon located?

Eikon is headquartered in Millbrae, United States. It is registered at 3929 POINT EDEN WAY, HAYWARD, CA 94545.

How many employees does Eikon have?

As of Jun 30, 2026, the latest employee count at Eikon is 429.

Is Eikon a funded company?

Eikon is a funded company, having raised a total of $1.16B across 4 funding rounds to date. The company's 1st funding round was a $148M Series A round, raised on May 05, 2021.

When was the latest funding round of Eikon?

Eikon's latest funding was a $351M Series D round on Feb 14, 2025, with participation from 11 investors.

Is Eikon a Oncology company?

The primary sectors of Eikon are Oncology, Immunology and Life Sciences Tech.

Where does Eikon rank among its competitors?

Eikon ranks 34th amongst 493 active competitors, of which 187 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of Eikon?

Eikon's top competitors include BeiGene, Biogen and Abcellera Biologics. Among them, DBV Technologies secured the most recent funding round in April, 2025.

Eikon - 2026 Company Profile, Team, Funding & Competitors

Eikon is a public company based in Millbrae (United States), founded in 2019 by Luke Lavis, Eric Betzig, Robert Tjian and Xavier Darzacq. It operates as a Protein tracking and measuring tool for drug discovery. Eikon has raised $1.16B in funding from investors like The Column Group, AME Cloud Ventures and General Catalyst. The company has 493 active competitors, including 187 funded and 118 that have exited. Its top competitors include companies like BeiGene, Biogen and Abcellera Biologics.

Sectors and market segments that Eikon operate in

Eikon serves in the Life Sciences, HealthTech market segments.The primary business model of Eikon are:

Company Details

Protein tracking and measuring tool for drug discovery. The company has developed a therapeutic discovery platform that assists researchers to analyze targeting protein dynamics for the drug discovery process. It uses technology platform that combines live-cell super-resolution microscopy, comuting and engineering.

Website: eikontx.com
Phone Number: +1 **********
Registered Address: 3929 POINT EDEN WAY, HAYWARD, CA 94545

Key Metrics

Founded Year

2019

Location

Millbrae, United States

Stage

Public

Total Funding

$1.16B in 4 rounds

Latest Funding Round

Series D, Feb 14, 2025, $351M

Investors

The Column Group & 23 more

Ranked

34^th among 493 active competitors

Employee Count

429 as on Jun 30, 2026

Similar Companies

BeiGene & 571 more

Exit Details

Public

View Eikon's full profile

Eikon is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
EIKON THERAPEUTICS, INC. CIN: 186372190 , United States, Active	Aug 27, 2021	-	-	-

Eikon got listed on Feb 05, 2026.

Click here to take a look at Eikon's IPO in detail

Eikon has raised a total funding of $1.16B over 4 rounds. Its first funding round was on May 05, 2021. Its latest funding round was a Series D round on Feb 14, 2025 for $351M. 11 investors participated in its latest round. Eikon has 24 institutional investors.

Here is the list of recent funding rounds of Eikon:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 14, 2025	$351M	Series D	-	-	-	Lux Capital, Alexandria, AME Cloud Ventures, The Column Group, E15VC, Foresite Capital, General Catalyst, StepStone Group, T. Rowe Price, Soros Capital Management, University of California
Jun 01, 2023	$141M	Series C	-	-	-	-
Jan 06, 2022	$518M	Series B	$3B	-	T. Rowe Price, CPP Investments, EcoR1, UC Investments, ADIA, Harel Group, StepStone Group, Schroders, General Catalyst, Hartford HealthCare, Foresite Capital, AME Cloud Ventures, E15VC, Innovation Endeavors, Lux Capital, Horizons Ventures, The Column Group, Schroeder Capital, soroscapital.eu	-

Access funding benchmarks and valuations. Sign up today!

View details of Eikon's funding rounds and investors

The founders of Eikon are Luke Lavis, Eric Betzig, Robert Tjian and Xavier Darzacq. Roger M Perlmutter is the CEO of Eikon.

Here are the details of Eikon's key team members:

Luke Lavis: Co-Founder of Eikon.
Contact Info: 1 email address
Eric Betzig: Co-Founder of Eikon.
Contact Info: 1 email address
Robert Tjian: Co-Founder of Eikon.
Contact Info: 1 email address
Xavier Darzacq: Former Co-Founder of Eikon.

View details of Eikon's Founder profiles and Board Members

Eikon's employee count trend

Eikon has 429 employees as of Jun 26. Here is Eikon's employee count trend over the years:

Uncover Eikon's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Eikon include BeiGene, Biogen and Abcellera Biologics. Here is the list of Top 10 competitors of Eikon, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
8th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T-cell receptor therapies for human diseases	$601M	BlackRock, General Atlantic & 50 others	69/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Lundbeck Foundation & 16 others	68/100
34th	Eikon 2019, Millbrae (United States), Public	Protein tracking and measuring tool for drug discovery	$1.16B	ADIA, Foresite Capital & 22 others	62/100